- Home
- MREO vs NPCE Comparison
MREO vs NPCE Comparison
Compare MREO & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | NPCE |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.6M | 328.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MREO | NPCE |
|---|---|---|
| Price | $2.02 | $16.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.20 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.4M | 266.7K |
| Earning Date | 11-10-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $500,000.00 | ★ $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | $131.12 | $1.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.47 | $7.56 |
| 52 Week High | $3.88 | $18.98 |
Technical Indicators
Market Signals| Indicator | MREO | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 63.36 |
| Support Level | $1.89 | $15.42 |
| Resistance Level | $2.37 | $16.94 |
| Average True Range (ATR) | 0.17 | 0.72 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 40.48 | 66.11 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.